Experienced in Myeloproliferative Neoplasms (MPN)

Sabrina Kraus

Oberdürrbacher Str. 6, 
Wuerzburg, BY, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Myeloproliferative Neoplasms (MPN)
Oberdürrbacher Str. 6, 
Wuerzburg, BY, DE 
OverviewLocationsClinical Research

Overview

Sabrina Kraus practices in Wuerzburg, Germany. Ms. Kraus is rated as an Experienced expert by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). Her top areas of expertise are Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Cytomegalovirus Infection, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 69 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Myeloproliferative Neoplasms (MPN).

Gender
Female

Locations

Oberdürrbacher Str. 6, Wuerzburg, BY 97080, Germany
Other Locations
Oberdürrbacher Street 6, Wuerzburg, BY 97080, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Treatment of Chemo-refractory Viral Infections After Allogeneic Stem Cell Transplantation With Multispecific T Cells Against CMV, EBV and AdV: A Phase III, Prospective, Multicentre Clinical Trial
Treatment of Chemo-refractory Viral Infections After Allogeneic Stem Cell Transplantation With Multispecific T Cells Against CMV, EBV and AdV: A Phase III, Prospective, Multicentre Clinical Trial
Enrollment Status: Recruiting
Publish Date: July 18, 2025
Intervention Type: Other
Study Phase: Phase 3
Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
Enrollment Status: Terminated
Publish Date: December 02, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

69 Total Publications

Performance of treatment response assessment at day 7 by baseline acute graft-vs-host disease severity.
Performance of treatment response assessment at day 7 by baseline acute graft-vs-host disease severity.
Journal: Transplantation and cellular therapy
Published: July 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kraus's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile